---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218162"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2026-05-12T11:11:58+00:00"
generated_at: "2026-05-12T11:16:46.660311+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q1 net loss $10.4M ($0.13/sh); cash runway into Q2 2028 after $90M offering

## Summary
- Net loss of $10.4M ($0.13 per share) vs $32.1M ($0.42) in Q1 2025; R&D spend fell to $13.6M.
- Cash, equivalents & securities of $84.8M at March 31; subsequent $90M offering extends runway to Q2 2028.
- Initiated Phase 1 trial of PRT12396, mutant-selective JAK2V617F inhibitor, in PV and MF patients.
- IND for KAT6A degrader PRT13722 expected by mid-2026; Phase 1 in ER+ breast cancer in 2H 2026.
- Appointed Charles Morris, M.D. as Chief Medical Officer in April 2026.

## SEC filing metadata
- accession: 0001193125-26-218162
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2026-05-12T11:11:58+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/0001193125-26-218162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/prld-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218162
- JSON: https://secwatch.observer/filing/0001193125-26-218162.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218162.txt

## Key facts
- Earnings Releases
  Prelude Therapeutics Inc reported financial results for the three months ended March 31, 2026.
  - Period: the three months ended March 31, 2026
  - Result: reported results
  source text: On May 12, 2026, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/0001193125-26-218162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.